ProQR Therapeutics (NASDAQ:PRQR – Get Rating) had its target price decreased by investment analysts at HC Wainwright from $4.00 to $2.00 in a note issued to investors on Monday, The Fly reports. HC Wainwright’s target price points to a potential upside of 212.45% from the stock’s current price.
PRQR has been the subject of several other reports. JMP Securities decreased their target price on shares of ProQR Therapeutics from $8.00 to $5.00 and set a “market outperform” rating for the company in a research report on Thursday, April 14th. Zacks Investment Research raised shares of ProQR Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research report on Tuesday, May 3rd. Citigroup downgraded shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, February 13th. Stifel Nicolaus downgraded shares of ProQR Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $20.00 to $3.00 in a research report on Friday, February 11th. Finally, Cantor Fitzgerald decreased their target price on shares of ProQR Therapeutics from $6.00 to $3.50 in a research report on Tuesday, April 19th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $6.59.
Shares of NASDAQ PRQR opened at $0.64 on Monday. The firm’s 50-day moving average price is $0.88 and its 200-day moving average price is $4.39. ProQR Therapeutics has a 1-year low of $0.64 and a 1-year high of $9.09. The firm has a market capitalization of $32.14 million, a P/E ratio of -0.60 and a beta of 0.97. The company has a current ratio of 6.94, a quick ratio of 5.10 and a debt-to-equity ratio of 0.35.
Several large investors have recently modified their holdings of PRQR. US Bancorp DE grew its holdings in shares of ProQR Therapeutics by 122.1% during the 3rd quarter. US Bancorp DE now owns 3,693 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 2,030 shares during the last quarter. Northern Trust Corp bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at $51,000. Dorsey Wright & Associates bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at $55,000. ProShare Advisors LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at $80,000. Finally, Coastal Bridge Advisors LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at $85,000.
ProQR Therapeutics Company Profile (Get Rating)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy.
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- ChemoCentryx: A Biotech Stock Well Worth the Risk
- Skechers Stock Can Be Bought on Pullbacks
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.